Company & Sponsor Intelligence
Allergan
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries1
Therapeutic footprint
epilepsymigraine_headacheout_of_scope
Indexed studies
NCT02959983Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
out_of_scope · United StatesPHASE4
out_of_scope · United StatesPHASE4
NCT01516892A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
migraine_headache · United StatesPHASE4
migraine_headache · United StatesPHASE4
NCT0377705912-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →